In 2007, our team demonstrated that the hetero-combination of antibodies against EGFR and HER2, two functionally collaborating receptors (Figure 1), has a higher anti-tumor effect by promoting ADCC, by reducing the expression of these receptors and homodimer formation [16,17,18] and also by inhibiting intracellular signaling pathways [19]. Here, ERBB2 is linked to neoplasm.